Built on ImpriMed’s myeloid expertise, xCellSense® applies ex vivo drug-sensitivity and synergy testing to high-risk MDS and the MDS-to-AML transition.
Request a Quote
High-risk MDS shares biology with AML and frequently progresses to AML. Venetoclax/HMA combinations and novel agents require functional positioning, and AML-transition risk shapes both patient selection and endpoint strategy.
1
Functional positioning
Sponsor asset ±venetoclax, HMA, and standard of care in live-derived primary MDS cells, with synergy quantification
2
Activity benchmarking
vs. standard of care in high-risk samples
3
Myeloid biomarker correlation
Genotype-to-response association using our AML methodology
4
Transition-relevant insight
Profiling oriented toward the high-risk MDS/AML-transition setting
MDS is supported by our extensive myeloid (AML) ex vivo program, which shares methodology, panel, and biology with high-risk MDS — applied to your MDS questions in a custom-designed study.
Functional positioning versus standard of care, AML-transition-relevant insight, and enrichment hypotheses for MDS trials.
Key Deliverables
A scientist — not a sales desk — will scope a tailored MDS study and return a design and timeline.
